Physician profile
James Mauch
NPI 1235124967
$5,027.44
in general payments reported to CMS, 2019-2025
26 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $550 · 2021: $1,161 · 2022: $1,625 · 2023: $487 · 2024: $37.68 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.05 |
| Education | $188.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $744.72 | 2019-2023 | |
| Abbvie INC. | $630.86 | 2019-2025 | |
| Amgen INC. | $579.55 | 2019-2025 | Otezla, Otezla |
| Genentech USA, INC. | $511.33 | 2019-2022 | |
| Janssen Biotech, INC. | $342.94 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $246.72 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $239.43 | 2022 | |
| Genzyme Corporation | $227.66 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $222.09 | 2019-2023 | Ilumya |
| Leo Pharma INC. | $175.70 | 2019-2022 | |
| Incyte Corporation | $171.60 | 2022 | |
| Lilly USA, LLC | $163.76 | 2021-2022 | |
| Celgene Corporation | $129.78 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.78 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $107.96 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $93.55 | 2019-2023 | |
| Almirall LLC | $66.92 | 2021-2022 | |
| Galderma Laboratories, L.P. | $60.06 | 2019-2022 | |
| Organogenesis INC. | $55.81 | 2022-2023 | Puraply |
| Dermavant Sciences, INC. | $43.61 | 2022-2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.17 | 2022-2023 | Spevigo |
| Aclaris Therapeutics, INC. | $20.80 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.58 | 2020 | |
| Arcutis Biotherapeutics, INC. | $13.29 | 2023 | |
| Dermira, INC. | $11.17 | 2020 | |
| Kerecis Limited | $8.60 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mauch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.